We are live on ! Find out more
CTC

Central Trust Company Portfolio holdings

AUM $5.08B
1-Year Est. Return 25.65%
This Fund
S&P 500
This Quarter Est. Return
+3.79%
1 Year Est. Return
+25.65%
3 Year Est. Return
+74.65%
5 Year Est. Return
+97.11%
10 Year Est. Return
+319.6%
AUM
$1.76B
AUM Growth
+$79.6M
Cap. Flow
+$3.6M
Cap. Flow %
0.2%
Top 10 Hldgs %
23.57%
Holding
1,206
New
105
Increased
295
Reduced
347
Closed
52

Sector Composition

Rank Sector Weight
1 Technology 13.61%
2 Healthcare 11.09%
3 Industrials 10.59%
4 Consumer Staples 10.19%
5 Financials 10.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GCVRZ
1201
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$0 ﹤0.01%
1,584
+50
+3% +$25

Similar funds

Central Trust Company's Q2 2019 Portfolio in Review

As of Q2 2019, Central Trust Company held 1,206 positions worth $1.76B, up 4.7% from $1.68B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Central Trust Company's Q2 2019 filing shows 105 new, 295 increased, 347 reduced and 52 closed positions. Its largest new stake was Dow Inc: 52,059 shares worth $2.49M. The largest sale was DuPont de Nemours, an estimated $3.63M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Industrials.

  • Central Trust Company's largest Q2 2019 buy was Dow Inc: 52,059 shares worth $2.49M.
  • Central Trust Company added most to Kellanova in Q2 2019, an estimated $2.42M increase.
  • Central Trust Company's biggest Q2 2019 reduction was DuPont de Nemours, cutting an estimated $3.63M.
  • Central Trust Company fully exited Universal Health Services in Q2 2019, selling an estimated $1.05M.
  • Central Trust Company's ten largest holdings make up 24% of its $1.76B portfolio in Q2 2019.
  • Central Trust Company opened 105 new positions and closed 52 in Q2 2019.
  • Central Trust Company's portfolio value rose 4.7% quarter-over-quarter to $1.76B.

Based on Central Trust Company's 13F filing for Q2 2019, filed 12 Jul 2019.